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Abstract:
Polymeric microparticles are micro carriers for the sustained drug delivery of drugs in
the lungs, used as alternatives to the use of established excipients. This study aims to
develop and characterize inhalable ciprofloxacin (CPx)‐loaded poly(vinyl alcohol) (PVA)
microparticles by a single‐step spray‐drying procedure. The optimization of the
processing parameters was achieved by an orthogonal design of the most relevant
processing parameters (polymer concentration, feed rate and inlet temperature). The
obtained spray‐dried particles showed a drug encapsulation efficiency higher than
90%. Furthermore, PVA‐CPx formulations, with drug contents up to 10 wt.%, showed a
morphology and size suitable for inhalation, with a sustained release profile over 24h.
Data from Fourier transformed infra‐red spectroscopy and differential scanning
calorimetry indicated absence of interaction between the polymer matrix and the
drug. Aerodynamic assessment of PVA‐CPx 10 wt.% was determined by the next
generation impactor (NGI), using spray‐dried CPx as a control. The results showed
improved values of mass median aerodynamic diameter (5.06
particle fraction (39.78
0.39

and 30.43

0.10

) and a fine

0.98 %) when comparing with the CPx alone (5.33

1.38 %). This study highlights the potential of spray‐dried PVA

microparticles as drug carriers for lung local delivery of antibiotics.

Abbreviations
PVA – Poly(vinyl alcohol); CPx – Ciprofloxacin; SD – spray‐dried; NGI – next generation
impactor; MMAD – mass median aerodynamic diameter; FPF – fine particle fraction;
DPI – dry powder inhaler.
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1 Introduction
The administration of pharmaceuticals via the pulmonary route has been a widely used
therapy to address pulmonary diseases such as asthma, cystic fibrosis, and chronic
infections. Lungs are an attractive delivery route for systemic therapies due to the
highly vasculated, large surface area (100 m2), thin alveolar epithelium (0.1‐0.2 m),
and low metabolic activity, which accounts for improved absorption and
bioavailability, when compared with intravenous and oral administration of drugs (Farr
and Otulana, 2006; Manca et al., 2015; Patton, 1996).
Regardless the final target site, the same key requirements must be accomplished to
have an effective therapeutic effect, which basically rely on device design and powder
formulation. Apart from the device performance itself, the powder formulation
properties such as particle size, flow, shape, surface properties and drug‐carrier
interaction, strongly influences the therapeutic dose (Atkins, 2005). The deposition site
is mainly driven by the particle mass median aerodynamic diameter (MMAD) and this
relationship establishes the size range between 1 and 5 m as the peak of particle
fraction that reaches the small airways and alveolar region (Labiris and Dolovich, 2003;
Patton and Byron, 2007), which increases the residence time in the lungs due to a
slower mucociliary clearance (Sakagami and Byron, 2005). Up to date, poly(lactic‐co‐
glycolic acid) (PLGA) is the most studied polymer for inhalable therapeutics owing to its
biocompatibility and biodegradability (Dailey et al., 2006; Hara et al., 2008). Ungaro et
al. (Ungaro et al., 2012) developed PLGA‐based nanoparticles for antibiotic
encapsulation, using hydrophilic helper polymers to modulate the release rate and the
lung deposition in a multistep processing. They added lactose as a microcarrier to
promote an efficient aerosolization of the nanoparticles, and showed an MMAD of
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3.4

1.7

5.7

1.8

with a fine particle fraction (FPF) of 52

1 and 38

1 %, respectively, for the formulations with the best performances. Rawat et al.
reported that heparin‐loaded PLGA microspheres produced by double emulsion
techniques were within the inhalable size range, but both the entrapment efficiency
(up to 55%) and half‐life (up to 6‐fold) were only increased by the addition of chemical
additives (Rawat et al., 2008). Manca and co‐workers also developed carriers for
pulmonary administration of rifampicin based on gelatin (Manca et al., 2013) and
polymer‐ coated liposomes (Manca et al., 2014), which displayed good aerodynamic
properties and an efficient drug internalization by A540 cells.
The in vivo effects of inhalable nanoparticles from alginate (Zahoor et al., 2005),
albumin (Woods et al., 2015) and chitosan (Trapani et al., 2013) also showed promising
results when compared with oral administration, although natural polymers often raise
some issues due to the presence of endotoxins (Pilcer and Amighi, 2010; Sivadas et al.,
2008).
There is a constant demand to use hydrophilic polymers, that can be used as vehicles
to carry and release the therapeutic agents in a controlled fashion. Poly(vinyl alcohol)
(PVA) is a synthetic water soluble polymer, completely biodegradable and its
microspheres as drug carriers have already been approved by Food and Drug
Administration (FDA) for embolization (Chaouat et al., 2008). PVA microspheres can be
prepared by electrospray (Felice et al., 2015), but the processing method is unstable
over time, with low yields and not scalable for an industrial application. On the other
hand, spray drying offer a unique opportunity to tune and optimize the processing
parameters from bench scale to large scale production.
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The orthogonal factorial design is a mathematical method to analyze a multifactorial
and multilevel process, which uses only a fraction of the experiments needed for a full
factorial design, still obtaining accurate estimates (Lee et al., 2013; Zheng et al., 2014).
This method allows to determine the relative importance of each factor and provides
the level optimization for each tested factor (Xie et al., 2015). Several works explored
this approach for the optimization parameters of polysaccharides extraction (RenJie,
2008) and electrospinning fibers (Vild et al., 2016; Xie et al., 2015), for the sensitivity
analysis of biometric systems (Lee et al., 2013) and optimization of laser‐induced
breakdown spectroscopy in aluminum alloys (Zheng et al., 2014). The use of a design of
experiments (DOE) approach, helps to determine which factors have more influence in
the process, saving experimental time and raw materials to establish the optimum
conditions.
In this work, the spray‐drying processing of inhalable polymeric particles was
optimized through an orthogonal design by the systematic manipulation of processing
parameters, using PVA (polyvinyl alcohol), a synthetic biocompatible and
biodegradable polymer, as a carrier.
Antibiotic therapy is often limited by systemic toxicity raised by the high doses
administrated by oral or parenteral formulations (Rybak et al., 1999). Hence, locally
and controlled delivery of antibiotics offers a potential alternative to overcome those
drawbacks. Ciprofloxacin (CPx), a broad‐spectrum fluoroquinolone used to treat
respiratory infections by oral and parenteral formulations, has been used as a model
drug in this study.
Accordingly, formulations of PVA‐CPx with CPx contents up to 10 wt.% were prepared
using the optimal conditions obtained from the orthogonal design. The developed
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formulations were characterized in terms of morphology, size distribution,
physicochemical and thermal properties, and in vitro release kinetics. The aerodynamic
performance of this formulation was also investigated in vitro using the next
generation impactor.

2 Material and methods
2.1 Materials
Poly(vinyl alcohol) (PVA; MW 85‐124 kDa; +99 % hydrolyzed), ciprofloxacin (CPx; purity
98 %), sodium chloride (NaCl), potassium chloride (KCl), sodium phosphate dibasic
(Na2HPO4), potassium phosphate monobasic (KH2PO4) and hydrochloric acid (HCl) were
purchased from Sigma‐Aldrich (Australia), and used as received. Deionized water was
produced by an Elix Essential 3 (Millipore) water purification system.

2.2 Microparticles processing
PVA and PVA‐CPx microparticles were obtained with an in‐house built spray drying
system, using PVA aqueous solutions as feed stock. For PVA‐CPx formulations, a stock
solution of CPx in 0.1 M HCl was added to the PVA solution to a final CPx concentration
of 2, 5, and 10 wt.%. Initially, the spray drying parameters were optimized for the drug
free PVA microparticles by an orthogonal design table

, using Orthogonal Design

Assistant II software (Sharetop Software Studio). The experimental parameters of feed
concentration, feed rate and inlet temperature are described in Table 1.
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2.3 Rheological analysis
The rheological behavior of feed stock solutions with different PVA concentrations
(0.5, 1 and 2 % w/v) was evaluated using a parallel plate ∅

20

geometry

rheometer (MCR 301, Anton Paar) with a 0.3 mm gap to ensure adequate filling of the
samples over the testing plate. Viscosity was measured as a function of shear rate
within the range of 1‐1000 s‐1, at 25 ºC.

2.4 Physico‐chemical characterization
2.4.1 Scanning electron microscopy (SEM)
The dry particles were coated with a 15 nm gold layer using a sputter coater (Smart
Coater, JEOL) and their morphology analyzed by scanning electron microscopy (JCM‐
6000PLUS Neoscope, JEOL), with an accelerating voltage of 15 kV. Particles average
diameter and their distribution was calculated over 300 particles from SEM
microphotographs (1,000 x magnification) using the Image J software (Schneider et al.,
2012). Particles dispersity was quantitatively evaluated by the coefficient of variation
, defined as

, where

represents the standard deviation of the mean

particle size ( ) (Felice et al., 2015).

2.4.2 Fourier Transform Infrared Spectroscopy (FTIR)
FTIR measurements were performed on dry powders using a Shimadzu IRAffinity‐1S
apparatus in ATR (attenuated total reflectance) mode from 4000 to 600 cm‐1, at room
temperature. FTIR spectra were collected after 24 scans with a resolution of 1 cm‐1.
Background spectra were subtracted from the sample ones.
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2.4.3 Raman Analysis
Raman spectra was performed on a Horiba Jobin Yvon LabRAM HR 800 Raman
spectrometer, using excitation of He‐Ne 632.8 nm with a power of 13.5 mW, and a
spectral resolution of 2 cm‐1.

2.4.4 Differential scanning calorimetry (DSC)
Differential scanning calorimetry measurements were performed with a Polyma 214
apparatus (Netzsch). Samples weighting around 5 mg were placed inside 40 L
aluminum pans with pierced lids, heated between 30 and 250 °C at a rate of 10 °C/min.
All experiments were performed under a nitrogen purge.

2.4.5 Thermogravimetrical analysis (TGA)
Thermogravimetrical analysis (TGA) was conducted in a TGA 4000 system
(PerkinElmer) using a heating rate scan of 20 ºC min‐1, under a nitrogen atmosphere.

2.4.6 Particle size distribution analysis
The size distribution of the PVA and PVA‐CPx 10 wt.% microparticles were determined
by laser diffraction using a Malvern Mastersizer 3000 (Malvern Instruments Ltd.) with a
Scirocco dry powder feeding cell. Samples ( 10 mg), analyzed in triplicates, were
dispersed in air using a feed pressure of 4 bar with an obscuration between 0.1 % and
10%, and a refractive index of 1.52.

2.4.7 Dynamic vapor sorption (DVS)

8
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The moisture sorption characteristics of PVA and PVA‐CPx 10 wt.% microparticles were
assessed by dynamic vapor sorption (DVS‐1 Intrinsic, Surface Measurement Systems
Ltd.). Samples (10‐30 mg) were dried at 0% relative humidity (RH) at 25ºC before
exposure to two sorption cycles from 0 to 90%, at 10% increments. At each stage, the
moisture sorption equilibrium was determined by a change in mass‐to‐time ratio
(

⁄ ) of 0.0005 %.min‐1.

2.5 Ciprofloxacin content
The CPx content was determined by re‐suspending the microparticles in 0.1 M HCl, in
ultrasonic bath (250 HD, Soniclean) for 6 h. The suspensions were centrifuged (10,000
rpm, 10 min) to remove the polymeric debris. CPx concentration was determined
spectrophotometer (UV1800, Shimadzu) at a wavelength of 277 nm, using a calibration
curve of CPx in HCl (0.1 M). Calibration standards were linear in the range of
0.5

15

⁄

0.999 . The drug content and entrapment efficiency were

calculated with Equation 1 and 2:

%

100

%

100

(1)

(2)

2.6 In vitro drug release
An accurately weighed quantity of PVA‐CPx formulations were transferred to a dialysis
membrane with a nominal cutoff of 1 kDa (Cellu.Sep H1, Fisher Biotec) keeping
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constant the CPx amount (914

). The membranes were then immersed in 200 mL of

PBS (pH 7.4), under magnetic stirring at 37 ºC. At predetermined time intervals up to
24 h, 2 mL of the release medium was withdrawn and replaced with fresh PBS. The
release experiments were designed to ensure sink conditions for CPx following a
previous work (Adi et al., 2010). The aqueous solubility of ciprofloxacin has been
reported to be 30 mg/mL at 20ºC (Varanda et al., 2006), hence CPx concentration in
our experiments (4.57

/

) would be 6500 times less than the solubility limit. The

release medium was measured at 270

using a spectrophotometer (UV1800,

Shimadzu) and the CPx concentration was calculated using a calibration curve of CPx in
PBS, with results expressed as % cumulative release relative to the initial weight of CPx
loaded in the particles. Analysis was performed in triplicates and results were
averaged.
The experimental results were fitted using the Korsmeyer‐Peppas model (Equation 3)
to further evaluate the release kinetics.

(3)

where

/

is a fraction of drug released at time ,

is the rate constant, and

is

the exponent that characterizes the release mechanism (Ritger and Peppas, 1987b;
Siepmann and Peppas, 2001).

2.7 In vitro aerodynamic performance
The aerodynamic properties of PVA and PVA‐CPx 10 wt.% microparticles was evaluated
using a next generation cascade impactor (NGI; Westech UK) equipped with an
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induction port, as per United States Pharmacopeia (USP) methodology. The flow rate
through the NGI was adjusted to 60 2 L.min‐1 using a pump and calibrated flow meter
(TSI 4040; TSI Instruments Ltd., USA). The PVA and PVA‐CPx microparticles were
loaded into size 3 gelatin capsules (Capsugel, Australia) and placed in the dosage
chamber of a high‐resistance dry powder device (DPI, RSO1, Plastiape, Italy). The
inhaler was connected to a 3D printed mouthpiece adaptor, that was inserted into the
USP induction port, and the microparticles were dispersed over a 4s period to simulate
one breath. Following actuation, the device, capsule, mouthpiece, throat, and all the
stages of the NGI were washed with MilliQ water. Ciprofloxacin was extracted in water
suspensions at 95 ºC for 1 h, sonicated for 30 min and filtered with a 0.45 m nylon
filter, prior to quantification. Each sample was tested in triplicate. Mass median
aerodynamic diameter (MMAD), geometric standard deviation (GSD) and fine particle
fraction (FPF) (mass of emitted dose with aerodynamic diameter

5

) were

calculated from the NGI results.

2.8. Data analysis
Quantitative data are presented as mean ± standard deviation (SD). Significant
differences were determined by one‐way ANOVA analysis with Tukey`s HSD post hoc
test or unpaired 2‐tailed t‐tests (for comparisons between two groups) using GraphPad
Prism Software (v 6.01). Statistical differences were considered when

11
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3 Results and Discussion
3.1 Particle processing
There is a demand for alternative excipients for pulmonary drug delivery and,
specifically for polymeric approaches which may assist in the aerosolization process
while promoting a more sustained release over time. However, there is yet limited
information relating the processing and performance of polymeric inhalable systems,
and those already available often involve complex multistep processing and /or the
need for an extra carrier or incorporation of additives to improve drug loading
efficiency (Rawat et al., 2008; Ungaro et al., 2012).
This work reports the development of inhalable polymeric particles for ciprofloxacin
lung delivery. A preliminary step was carried out to optimize the spray‐drying
parameters for PVA alone. Using an orthogonal design (Vild et al., 2016), three factors
(feed concentration, feed rate and inlet temperature) were screened among three
levels (Table 1) and the effects were evaluated by obtained mean particle diameter
(Table S1 and Figure S1 for size distributions). The water content (Figure S2) calculated
by the TGA profiles in the region of water evaporation, ranged between 0.3 and 5.5%
for all the experimental runs. The impact of these factors on the particle diameter is
depicted in Figure 1a, where the increase of feed concentration appears to induce an
increase in particle size, despite the similarity in the feed solution viscosity for the
tested concentrations (Figure 1b).
Indeed, the determination of the range values ( ) (Table 2) attributed to the feed
concentration the highest impact on the process, followed by the feed rate and inlet
temperature. Accordingly, the optimal levels were settled as levels 1, 3 and 1 for
concentration (0.5 % w/v), feed rate (308 mL.h‐1) and inlet temperature (105 ºC),
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respectively. Despite this, the feed rate used in this experiment was reduced to level 2
(206 mL.h‐1), due to the accumulation of water vapor on the collecting jar, jeopardizing
particle integrity and leading to a non‐continuous process.
PVA microparticles containing ciprofloxacin were formulated by spray‐drying of a
single feed aqueous solution, thus avoiding the use of organic solvents. The obtained
PVA‐CPx formulations were characterized by an overall smooth surface with a
spherical morphology, nevertheless, the presence of a few irregular particles with
external voids was detected (Figure 2 ‐ insets). The increase of CPx content did not
significantly changed particle size distribution (Figure 2), with average mean diameters
ranging from 2.39

0.76

(PVA alone) to 2.84

0.95

(10 wt.% of CPx),

demonstrating the narrow size of the particles, regardless the drug content. This was
also corroborated by the low coefficients of variation (0.3 ‐ 0.4) among the
formulations, evidencing the process reproducibility and scalability. Overall, the
physical diameter distributions depicted in Figure 2 were a good indicator of the
suitability of these formulations for inhalation (Patton and Byron, 2007).

3.2 Physicochemical characterization of microparticles
The IR spectra of the PVA, spray‐dried ciprofloxacin (SD‐CPx) and the PVA‐CPx
microparticles are depicted in Figure 3a. The major absorption bands of PVA are clearly
identified for the PVA‐CPx formulation. The absorption band between 3550 ‐ 3200 cm‐1
are assigned to the

groups. The bands at 2941 and 2912 cm‐1 represent the

asymmetrical and symmetrical stretching vibration of
Secondary in‐plane

bending and

in the PVA backbone.

wagging is observed at 1415 and 1330
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cm‐1. The two absorption bands at 1139 and 1087 cm‐1 are due to the

and

stretching vibration, respectively (Mansur et al., 2008; Zhang et al., 2010).
Ciprofloxacin characteristic absorption bands were identified in SD‐CPx spectrum. The
bands at 3084 and 2918 cm‐1 were assigned to the

stretching vibration from the

phenyl framework; the band at 1713 cm‐1 was addressed to the

stretching

vibration, whereas vibration of the phenyl framework conjugated to the carboxylic acid
is at 1616 cm‐1 (Dong et al., 2006; Wang et al., 2007). The stretching vibration of the
bonds appears at 1266 cm‐1. Despite most of the CPx vibration modes were
overlapped by the stronger PVA absorption bands, it was possible to identify CPx
characteristic bands in the PVA‐CPx formulations; additionally, there were no new
vibrational modes nor suppression, which indicates the lack of chemical interaction
between the drug and the polymer.
The Raman spectra (Figure 3b) enabled to confirm the presence of CPx characteristic
peaks. The strongest Raman bands of CPx were detected in the PVA‐CPx formulation,
specifically at 1383 and 1464 cm‐1 attributed to

symmetrical and

asymmetrical stretching vibration, respectively (Yang et al., 2015). The peak at 1549
cm‐1 was assigned to the stretching vibration of the quinolone ring, and the band at
1625 cm‐1 was attributed to the

asymmetrical vibration of the aromatic rings

(Yang et al., 2015).
The thermal properties of the SD‐CPx, PVA and the PVA‐CPx microparticles were
evaluated by DSC. SD‐CPx showed to be stable at temperatures up to 250 ºC (Figure 4).
PVA and PVA‐CPx microparticles presented a broad endothermic peak in the
temperature range of 30 and 120 ºC, assigned to the evaporation of bounded water
(Figure 4). The melting of the PVA microparticles started at ~ 180 ºC, with a maximum
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peak temperature of 220 ºC. Furthermore, the polymer melting temperature remained
unchanged after incorporation of the drug, suggesting that the drug and the polymer
did not have a chemical affinity.
The degree of crystallinity (∆ ) of the PVA and PVA‐CPx particles was calculated
according to:

∆

∆
∆

(4)

where, ∆

and ∆

are the sample melting enthalpy, and the enthalpy for 100%

crystalline PVA polymer (168 J/g) (Wu et al., 2010). PVA unloaded microparticles had a
crystallinity degree of 35%, while the samples with 10 wt.% CPX had a ∆ of 40%,
suggesting that the drug could act as a nucleation agent, leading to an increase in
polymer crystallization (Wang et al., 2007).
The Hansen solubility parameters for the drug and polymer matrix is presented in
Table 3. It is reported that compounds with similar values of solubility parameter,
nominally ∆

7.0 MPa1/2, are more likely to be miscible, whereas if ∆

10.0

MPa1/2, the compounds are most probably immiscible (Greenhalgh et al., 1999). The
solubility parameter of PVA is 26.34 MPa1/2, and the CPx is 24.15 MPa1/2 (Barton, 1990;
Shah and Agrawal, 2012). The difference in the solubility parameter for the polymer‐
drug interaction can be estimated from:

∆

/
,

,

,

,

,

15

,

(5)
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where, ,

and

indicate the polar, dispersive and hydrogen bonding components,

respectively, while the symbols

and

identify the polymer and drug, respectively.

The difference of solubility parameter between the drug and the polymer matrix was
9.24 MPa1/2, which suggests that a miscibility between the polymer and the drug is
unlikely to occur. The analysis of the Hansen solubility parameters corroborates the
chemical (figure 4) and thermal analysis (figure 5) recorded for the polymer‐drug
microparticles.
The inhalable potential of the formulation containing 10 wt.% of CPx was further
assessed by the volumetric diameter measured by laser diffraction, which is depicted
in Figure 5. The volume‐weighted of SD‐CPx showed a median volume diameter of
7.18

0.20

(Figure 5 – inset) along with an irregular, crystalline‐like morphology

(Figure S3). On the other hand, spray‐dried PVA particle size distribution was very
similar to the PVA‐CPx 10 wt.% microparticles. These formulations exhibited a tri‐
modal profile with the predominant population in the range of 1‐10

; hence, the

median volume diameter of the PVA and PVA‐CPx was determined as 3.30
and 3.20

0.13

0.03

, respectively, which correlates with the diameter estimation from

SEM microphotographs, and lies within the optimum inhalable size range (Healy et al.,
2014). Moreover, SD‐CPX particle span (

.

.

/

.

) indicates that the

SD‐CPx have a wide particle size distribution, when compared to the polymeric carriers
(Figure 5).
The physical stability of the formulations under a variety of humidity conditions at
constant temperature of 25ºC was evaluated by dynamic vapor sorption (DVS). The
moisture sorption‐desorption profiles (Figure 6) of SD‐CPx, PVA and PVA‐CPx showed a
maximum mass change of 1.9%, 25% and 23%, respectively, at a 90% RH. All
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formulations exhibited reversible isotherms with only minimal hysteresis, which
indicates that despite being moisture sensitive, this effect is reversible. These results
agree with a previous work using PVA‐drug particles (Salama et al., 2008a), which
reports a water absorption profile up to 90% RH, where a maximum mass change
about 25% for the formulation containing 90 wt.% PVA was reported.

3.3 In vitro studies: CPx loading and drug release
The PVA‐CPx microparticles were produced in a single ‐step by spray‐drying of an
environmentally friendly aqueous solution with high encapsulation efficiencies (> 90%,
Table 4). The increase of CPx up to 10 wt.% related to the PVA mass did not affect the
drug entrapment, suggesting the potential to further tailor CPx loading of PVA
formulations, according to the clinical requirements.
There is no standard in vitro methodology for assessing drug release profile from
polymeric inhaled powders that mimics the lung environment (Salama et al., 2008b);
however, the dialysis membrane method has been extensively used and its regarded
as a suitable set up to assess drug dissolution in the lungs (Tewes et al., 2016).
The release profiles over time for the different formulations at physiologic conditions
(pH 7.4, and 37 °C) are shown in Figure 7. SD‐CPx presented a burst release (90%)
during the first hour, while PVA formulations showed a sustained release of
ciprofloxacin over 24h. Formulations with lower CPx contents (2 and 5 wt.%) presented
similar release profiles, while the 10 wt.% formulation showed a rapid initial release
after 10 minutes (40.1

7.0%), representing approximately a 4‐fold increase

comparing with the lowest CPx formulations (8.0

0.4% and 12.1

2.5%). The

increasing of CPx content probably lead to spatial constraints and to an increase of the
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CPx molecules closer to the microparticle boundaries, thus reducing the diffusion path
of the drug, boosting its initial release.
The experimental data was modelled using the Korsmeyer‐Peppas model for the first
hour, where

⁄

0.6 (Bruschi, 2015), and the kinetic parameters are presented

in Table 5. The estimation of the parameter

corroborates that higher CPx content

increases the release rate when comparing with lower formulations (p<0.001). The
values of the release exponent

for the different formulations also reflects distinct

release mechanisms. For a spherical geometry,

0.43 is indicative of Fickian

diffusion, whereas a superimposition of drug diffusion and polymer chain relaxation is
described by 0.43

0.85 (Ritger and Peppas, 1987a; Siepmann and Peppas,

2001). Our results suggest that the increase in the CPx content leads to a primarily
diffusion‐dependent release mechanism, while for the lower CPx formulation the
release mechanism relies on the superimposition of both phenomena (drug diffusion
and polymer chain relaxation).
However, these results are merely indicative of the microparticles performance in the
PBS. For instance, a study by Arora et al. (Arora et al., 2015) using dry powder
formulations of voriconazole, reports differences in the kinetic parameters upon
different in vitro methodologies, which are related to the water content in the system.

3.4 In vitro aerodynamic performance
Aerodynamic performance of the spray‐dried formulations was tested using the NGI
for the assessment of the lung deposition pattern of the drug. The particle deposition
on each stage of the NGI is plotted in Figure 8. For both formulations, SD‐CPx and PVA‐
CPx, the delivered dose was 72.16

1.76 % and 84.08

18
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dose, respectively. Some degree of particle aggregation may have occurred since a
substantial fraction of the powder was deposited in the throat and in the upper NGI
stages, which also explains the increased aerodynamic median diameter compared
with geometric estimation. Nevertheless, PVA‐CPx deposition showed a significant
decrease in the device and throat when compared with the SD‐CPx, and an increase in
the lower stages of the NGI. Better aerodynamic features were also obtained for the
PVA‐based formulation rather than SD‐CPx; despite presenting similar MMAD and GSD
values, the determined FPF (<5
higher (

) for PVA‐CPx (39.78

0.01) than SD‐CPx (30.43

0.98 %) was statistically

1.38 %), meaning that this fraction can reach

the deep lungs. The obtained parameters are above the range of conventional dry
powder inhaler formulations (15‐30 %) (Saigal et al., 2013; Smith and Parry‐Billings,
2003).
Other authors have reported the production of inhalable PVA‐based formulations with
different FPF values. Salama and co‐workers (Salama et al., 2008a) described a linear
relationship between PVA content and FPF, achieving 30.76

1.5 % for a PVA content

of 90% (w/w). Other PVA‐based systems for the encapsulation of nifedipine by spray‐
drying, presented MMAD between 8.05 and >13
and 34.9

and a FPF between 20.4

2.47

2.4 % (Saigal et al., 2013).

4 Conclusion
This study provides an insight in the processing and performance of inhalable spray‐
dried formulations of PVA for the delivery of ciprofloxacin. An orthogonal design was
used to assess the effect of the processing parameters in the particle´s distribution

19

https://doi.org/10.1016/j.ijpharm.2018.05.060

diameter. The order of importance of each factor was determined as polymer
concentration > feed rate > inlet temperature.
The incorporation of ciprofloxacin up to 10 wt.% was achieved under the optimal
processing parameters, with efficiencies higher than 90 %, using a simple and scalable
process with in vitro profiles showing a sustained release over 24 h. Moreover,
preliminary aerosolization studies using a NGI confirmed the suitability of the
formulation to be administrated as a DPI, showing a FPF (<5

) of 39.78

0.98 %.

Overall, this study describes a promising platform for the pharmaceutical tailoring of
DPIs using a synthetic, biodegradable and GRAS (generally regarded as safe) polymer.
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Figure Captions

Figure 1 – Orthogonal design: (a) dependence of average particle diameter and
coefficient of variation (Cv) on the processing factors and levels by spray‐drying,
determined by measurements using Image J software; (b) viscosity of PVA feed
solutions (0.5%, 1% and 2% w/v) as a function of the shear rate measured at 25ºC (b).

Figure 2 – Particle size distribution of PVA with different CPx contents (0, 2, 5 and 10
wt.%). Insets: representative electron micrographs of (a) PVA and (b) PVA‐CPx 10 wt.%
microparticles (scale bar: 5 m).

Figure 3 – Fourier transformed infrared spectra (a) and Raman spectra (b) of the spray‐
dried formulations.

Figure 4 ‐ DSC of spray‐dried ciprofloxacin and PVA formulations.

Figure 5 – Volume‐weighted particle size distribution and geometric parameters (inset)
of SD‐CPx, PVA and PVA‐CPx 10wt.% formulations measured by laser diffraction.

Figure 6 – Dynamic vapor sorption isotherms (a ‐ c) and mass change versus time (d ‐ f)
for SD‐CPx, PVA and PVA‐CPx 10wt.% formulations.
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Figure 7 – Ciprofloxacin release profiles from free SD‐CPx and PVA‐CPx formulations
using dialysis membrane method in PBS (pH 7.4) at 37 0.5 . Values are presented
as average SD of 3 measurements.

Figure 8 – Aerodynamic particle size distribution obtained by NGI at a flow rate of 60
L/min. Inset: Aerodynamic parameters for the PVA‐CPx spray‐dried formulation
compared with spray‐dried CPx as a control. Results are presented as mean SD
(
3; ∗
0.05,∗∗
0.01,∗∗∗
0.001).
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